TR201720642A2 - Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ - Google Patents

Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ Download PDF

Info

Publication number
TR201720642A2
TR201720642A2 TR2017/20642A TR201720642A TR201720642A2 TR 201720642 A2 TR201720642 A2 TR 201720642A2 TR 2017/20642 A TR2017/20642 A TR 2017/20642A TR 201720642 A TR201720642 A TR 201720642A TR 201720642 A2 TR201720642 A2 TR 201720642A2
Authority
TR
Turkey
Prior art keywords
cafe
guided
microvesicular
loaded
improvement
Prior art date
Application number
TR2017/20642A
Other languages
English (en)
Inventor
Nesli̇han Taşli Paki̇ze
Şahi̇n Fi̇kretti̇n
Apdi̇k Hüseyi̇n
Avşar Apdi̇k Ezgi̇
Kaan Kirbaş Oğuz
Original Assignee
Univ Yeditepe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yeditepe filed Critical Univ Yeditepe
Priority to TR2017/20642A priority Critical patent/TR201720642A2/tr
Priority to EP18894456.5A priority patent/EP3727590A4/en
Priority to RU2020123531A priority patent/RU2785400C2/ru
Priority to US16/955,087 priority patent/US11510891B2/en
Priority to CN201880089594.4A priority patent/CN112020380A/zh
Priority to AU2018395740A priority patent/AU2018395740B2/en
Priority to PCT/TR2018/050816 priority patent/WO2019132831A2/en
Priority to JP2020533249A priority patent/JP7509423B2/ja
Priority to CA3086056A priority patent/CA3086056A1/en
Publication of TR201720642A2 publication Critical patent/TR201720642A2/tr
Priority to US17/840,700 priority patent/US12138235B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bu buluş özelleşmiş deri hücrenin besi solüsyonuna bıraktığı mikrovesiküllere KAFE yüklemesi yapılarak SH-SY5Y nöroblastoma kanserine spesifik etkili bir ilaç üretimi ile ilgilidir. Buluşun amacı, doku hücrelerinin kültürü ve ardından özelleştirilmesi sonucunda elde edilen mikrovesiküllere KAFE yüklenerek hücreye spesifik güdümlü bir vesikül geliştirilmesinin ve tekniğin bilinen durumundaki uygulamalara kıyasla daha düşük konsantrasyonlarda KAFE kullanılmasıyla hem güdümlü olduğu hücreler dışındaki diğer hücrelere hem de vücuda yönelik toksisitesinin en aza indirgenmesinin sağlanmasıdır.
TR2017/20642A 2017-12-18 2017-12-18 Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇ TR201720642A2 (tr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
TR2017/20642A TR201720642A2 (tr) 2017-12-18 2017-12-18 Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇
EP18894456.5A EP3727590A4 (en) 2017-12-18 2018-12-17 CAPE-LOADED TARGETED MICROVESICULAR CANCER MEDICINE AND METHOD OF DEVELOPING IT
RU2020123531A RU2785400C2 (ru) 2017-12-18 2018-12-17 Противораковое лекарственное средство в форме cape-нагруженных микровезикул направленного действия и способ его разработки
US16/955,087 US11510891B2 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same
CN201880089594.4A CN112020380A (zh) 2017-12-18 2018-12-17 Cape-装载的靶向微囊泡癌症药物及其开发方法
AU2018395740A AU2018395740B2 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same
PCT/TR2018/050816 WO2019132831A2 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same
JP2020533249A JP7509423B2 (ja) 2017-12-18 2018-12-17 Ｃａｐｅロードされた標的化微小胞抗がん剤およびその開発方法
CA3086056A CA3086056A1 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same
US17/840,700 US12138235B2 (en) 2017-12-18 2022-06-15 Cape-loaded targeted microvesicular cancer drug and method for developing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/20642A TR201720642A2 (tr) 2017-12-18 2017-12-18 Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇

Publications (1)

Publication Number Publication Date
TR201720642A2 true TR201720642A2 (tr) 2019-07-22

Family

ID=67066521

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/20642A TR201720642A2 (tr) 2017-12-18 2017-12-18 Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇

Country Status (8)

Country Link
US (2) US11510891B2 (tr)
EP (1) EP3727590A4 (tr)
JP (1) JP7509423B2 (tr)
CN (1) CN112020380A (tr)
AU (1) AU2018395740B2 (tr)
CA (1) CA3086056A1 (tr)
TR (1) TR201720642A2 (tr)
WO (1) WO2019132831A2 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201720642A2 (tr) * 2017-12-18 2019-07-22 Univ Yeditepe Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇
KR102132457B1 (ko) * 2019-05-10 2020-07-09 주식회사 바이오솔루션 세포외 소포를 고농도로 배양하기 위한 세포 배양배지 및 상기 세포 배양배지를 이용한 세포외 소포 고 함유 조건화 배양액의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932517A3 (en) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
AU2009203638C1 (en) * 2008-01-04 2013-07-25 Lydac Neuroscience Limited Microvesicles
WO2013012477A1 (en) * 2011-05-20 2013-01-24 New York University Propolis and caffeic acid phenethyl ester and uses thereof
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
CA2910802A1 (en) * 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles
US20170209499A1 (en) * 2014-07-18 2017-07-27 Manuka Health New Zealand Limited Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health
CN106692984B (zh) * 2016-12-08 2020-02-18 武汉大学 一种基于细胞源性微囊泡的肿瘤靶向递送载体及制备方法和应用
TR201720642A2 (tr) * 2017-12-18 2019-07-22 Univ Yeditepe Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇

Also Published As

Publication number Publication date
CA3086056A1 (en) 2019-07-04
AU2018395740B2 (en) 2024-02-15
WO2019132831A2 (en) 2019-07-04
US12138235B2 (en) 2024-11-12
JP7509423B2 (ja) 2024-07-02
RU2020123531A (ru) 2022-01-20
US11510891B2 (en) 2022-11-29
EP3727590A2 (en) 2020-10-28
EP3727590A4 (en) 2021-09-29
JP2021508320A (ja) 2021-03-04
AU2018395740A1 (en) 2020-07-09
US20220362194A1 (en) 2022-11-17
US20210023038A1 (en) 2021-01-28
WO2019132831A3 (en) 2019-09-26
CN112020380A (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
CY1122155T1 (el) Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης
AU2017225061B2 (en) Biomarkers and methods of treating PD-1 and PD-L1 related conditions
EA201991369A1 (ru) Модифицированные направляющие рнк
EA201991555A1 (ru) Композиции и способы усиления или увеличения продукции ifn i типа
MX2017010795A (es) Proteínas biológicas condicionalmente activas.
EA202190474A1 (ru) Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
MX2021000295A (es) Compuestos inmunomoduladores dimericos contra mecanismos basados en cereblon.
MX381260B (es) Inhibidores heterociclicos de glutaminasa.
WO2014183066A3 (en) Protein modification of living cells using sortase
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX379539B (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
MX2014003832A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
PE20170776A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CY1123489T1 (el) Μεθοδοι θεραπειας του καρκινου με ημιζυγωτικη απωλεια του tp53
BR112015033053A2 (pt) método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
CY1116186T1 (el) Μακροκυκλικες ενωσεις και μεθοδοι για την παραγωγη τους
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
BR112014024487A2 (pt) métodos para aumentar a eficácia da terapia baseada em cd37
EP4328319A3 (en) Methods and compositions for identifying and treating patients with small cell lung cancer
CY1117234T1 (el) Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης
TR201720642A2 (tr) Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇
BR112017020013A2 (pt) método para preparação de um substituto da pele, substituto da pele, substituto dérmico, enxerto, enxerto para uso, e kit para implementação do método
EA202192289A1 (ru) Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений